Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 6/20 | 0.77 |
| ▸ | P2RY1 | P47900 | 7/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.67 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.63 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195866 | 0.99 | RNASEL (0.75) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL30047050 | 0.99 | RNASEL (0.75) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL29423355 | 0.92 | RNASEL (0.89) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL29494944 | 0.92 | RNASEL (0.72) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL2463663 | 0.92 | RNASEL (0.72) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL30055318 | 0.91 | RNASEL (0.87) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL29814022 | 0.88 | RNASEL (0.67) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL16700308 | 0.88 | RNASEL (0.67) | RNASELP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL20266295 | 0.88 | RNASEL (0.61) | RNASELP2RY1P2RY12 | |
| SCHEMBL30969952 | 0.88 | RNASEL (0.61) | RNASELP2RY1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960131-B2 | Functional genomic pore assay for mixed cell populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | claimed |
| US-7560243-B2 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-14 | — | — | US | claimed |
| US-20090053204-A1 | Functional Genomic Pore Assay For Mixed Cell Populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | US | claimed |
| WO-2005079250-A2 | PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20040253650-A1 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-16 | — | — | US | claimed |
| US-20030059878-A1 | Novel purinoceptor and gene thereof | TANABE SEIYAKU CO., LTD (JP) | 2003-03-27 | — | — | US | claimed |
| US-5492898-A | ADMINISTERING ALKYLTHIO-NUCLEOTIDE DERIVATIVES TO REDUCE OR PREVENT SHOCK CAUSED BY BACTERIAL ENDOTOXINS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-02-20 | — | — | US | claimed |
| CN-107029237-B | Application of thermogenesis enhancing compound in enhancing thermogenesis of noradrenaline compound induced brown fat cells | 康建胜 | 2021-06-25 | — | — | CN | disclosed |
| EP-2049127-B1 | N-METHANOCARBA DERIVATIVES TO TREAT CARDIAC DISEASES | UNIV CONNECTICUT (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014170343-A1 | DEPOLARIZING AGENTS AND NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING DOPAMINERGIC-RELATED DISORDERS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2014-10-23 | — | — | WO | disclosed |
| US-8410078-B2 | Composition and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-7960131-B2 | Functional genomic pore assay for mixed cell populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | disclosed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | disclosed |
| US-20040253650-A1 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-16 | — | — | US | disclosed |
| US-20030059878-A1 | Novel purinoceptor and gene thereof | TANABE SEIYAKU CO., LTD (JP) | 2003-03-27 | — | — | US | disclosed |
| WO-1999043326-A1 | USE OF A CARDIAC PURINOCEPTOR TO EFFECT CELLULAR GLUCOSE UPTAKE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5492898-A | ADMINISTERING ALKYLTHIO-NUCLEOTIDE DERIVATIVES TO REDUCE OR PREVENT SHOCK CAUSED BY BACTERIAL ENDOTOXINS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053612-A1 | Nucleotide regulation of immune responses | NT5C2, ENTPD5, ENTPD1 | RNASEL 664/4885P2RY1 7/4885P2RX1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.